LC
PBYI icon

Lindbrook Capital’s Puma Biotechnology PBYI Stock Holding History

Lindbrook Capital’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-2,793
Closed -$12.1K – 2730
2023
Q4 		$12.1K Hold
2,793
– – ﹤0.01% 1442
2023
Q3 		$7.35K Hold
2,793
– – ﹤0.01% 1572
2023
Q2 		$9.86K Hold
2,793
– – ﹤0.01% 1476
2023
Q1 		$8.63K Hold
2,793
– – ﹤0.01% 1540
2022
Q4 		$11.8K Hold
2,793
– – ﹤0.01% 1352
2022
Q3 		$7K Hold
2,793
– – ﹤0.01% 1505
2022
Q2 		$8K Hold
2,793
– – ﹤0.01% 1357
2022
Q1 		$8K Hold
2,793
– – ﹤0.01% 1393
2021
Q4 		$8K Hold
2,793
– – ﹤0.01% 1367
2021
Q3 		$20K Hold
2,793
– – 0.01% 751
2021
Q2 		$26K Hold
2,793
– – 0.01% 690
2021
Q1 		$27K Hold
2,793
– – 0.01% 641
2020
Q4 		$29K Hold
2,793
– – 0.01% 568
2020
Q3 		$28K Hold
2,793
– – 0.01% 514
2020
Q2 		$29K Hold
2,793
– – 0.01% 498
2020
Q1 		$24K Hold
2,793
– – 0.01% 492
2019
Q4 		$24K Buy
+2,793
New +$23.1K 0.01% 675

Other funds holding PBYI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
ACM
Athyrium Capital Management New York $8.69M AUM 34.58% 1-Year Est. Return

Lindbrook Capital's PBYI Position: Q1 2024 in Review

Lindbrook Capital sold out of Puma Biotechnology (PBYI) in Q1 2024, closing a stake of 2,793 shares — an estimated $12.1K sold.

Lindbrook Capital first reported a position in PBYI in Q4 2019 and held it in 17 quarters. The position peaked at $29K in Q4 2020. 93 funds tracked by Wall St. Rank hold PBYI as of Q1 2024.

  • Lindbrook Capital reported no remaining Puma Biotechnology position as of Q1 2024 after selling out during the quarter.
  • Lindbrook Capital sold 2,793 Puma Biotechnology shares in Q1 2024, an estimated $12.1K.
  • Lindbrook Capital first reported a position in Puma Biotechnology in Q4 2019 and held it in 17 quarters.
  • Lindbrook Capital's Puma Biotechnology position peaked at $29K in Q4 2020.
  • 93 funds tracked by Wall St. Rank held Puma Biotechnology as of Q1 2024.

Based on Lindbrook Capital's 13F filing for Q1 2024, filed 25 Apr 2024.